(Q32058552)

6 July 2017

1 reference

title

The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy (English)

1 reference

6 July 2017

main subject

anti-retroviral agent

0 references

author name string

G Moyle

series ordinal

1

1 reference

6 July 2017

publication date

1 January 2001

1 reference

6 July 2017

1 reference

6 July 2017

volume

61

1 reference

6 July 2017

issue

1

1 reference

6 July 2017

page(s)

19-26

1 reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

6 July 2017

cites work

1 reference

12 December 2020

Efavirenz: shifting the HAART paradigm in adult HIV-1 infection.

1 reference

12 December 2020

Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use

1 reference

12 December 2020

1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee

1 reference

12 December 2020

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

12 December 2020

Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice

1 reference

12 December 2020

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

1 reference

12 December 2020

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

12 December 2020

Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy.

1 reference

12 December 2020

A risk-benefit assessment of HIV protease inhibitors

1 reference

12 December 2020

10.2165/00003495-200161010-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

6 July 2017

1043424483

0 references

1 reference